▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

Sapio Sciences Makes AI-Native Drug Discovery Seamless with NVIDIA BioNeMo

Sapio Sciences, the science-aware™ lab informatics platform, today announced the integration of the NVIDIA BioNeMo platform into the Sapio Lab Informatics Platform. This integration brings AI-driven...

Business Wire

Integration of the NVIDIA BioNeMo platform enhances AI capabilities across the drug discovery lifecycle

BALTIMORE: Sapio Sciences, the science-aware™ lab informatics platform, today announced the integration of the NVIDIA BioNeMo platform into the Sapio Lab Informatics Platform. This integration brings AI-driven computational drug discovery directly into Sapio ELN (Electronic Lab Notebook), helping to streamline workflows and improve decision-making in drug discovery.

With the BioNeMo platform, researchers can accelerate drug discovery by leveraging science-specific AI frameworks, pre-trained models, and generative AI tools to streamline the identification of potential drug candidates and improve target selection accuracy. NVIDIA BioNeMo provides scientists with a framework for training and deploying large biomolecular language models at supercomputing scale.

The integration of BioNeMo into the Sapio Platform provides scientists with embedded in silico tools, enabling them to, for example, generate novel candidate molecules early in the research process and test their docking with a target protein. With AI-driven molecular simulations available within a single, unified workflow, researchers can streamline their processes, enhance innovation, and accelerate the transition from discovery to development.

Within Sapio ELN, researchers can access BioNeMo NIM microservices to rapidly identify and optimize drug candidates using AI-driven molecular modeling, including AlphaFold2 NIM for predicting accurate 3D protein structures; MoIMIM NIM to enable the design and optimization of small molecules; and DiffDock NIM, an AI-powered docking model developed by MIT. These models provide scientists with easy access to AI-driven tools without extensive setup, ensuring faster, more efficient research workflows.

Kevin Cramer, Founder, CEO & CTO at Sapio Sciences, commented: “AI innovation is advancing rapidly, but scientists are often forced to navigate fragmented tools with complex interfaces, slowing down research. Our integration of NVIDIA’s powerful AI-driven tools directly into the Sapio Platform enables researchers to apply AI seamlessly into their experiments. Through this work, we are removing inefficiencies and equipping scientists with the tools to rapidly generate, analyze, and visualize both chemical and biological results.”

Kevin continued: “We are working with NVIDIA to equip scientists and researchers with the most advanced AI tools to drive innovation in life sciences. This collaboration is a major step toward making AI an integral part of the drug discovery process, helping researchers make faster, data-driven decisions and improve research outcomes.”

Anthony Costa, Director, Digital Biology at NVIDIA, commented: “Integrating BioNeMo into Sapio’s AI-driven research platform gives scientists access to advanced generative AI models for drug discovery. With AlphaFold2, MoIMIM, and DiffDock NIMs, researchers can predict, optimize, and validate drug candidates with greater speed and accuracy. This work underscores AI’s growing role in transforming pharmaceutical research and accelerating the path to breakthrough treatments.”

Integrating NVIDIA technologies into the Sapio Platform is one of the many ways Sapio Sciences is helping to improve and accelerate biopharma discovery, clinical diagnostics, and drug manufacturing.

Find out more about the Sapio/NVIDIA integration here.

About Sapio Sciences

At Sapio Sciences, our mission is to improve lives by accelerating the entire drug lifecycle. Our cloud-based solutions—LIMS, ELN, and Scientific Data Management—are unified on a flexible, configurable, and AI-powered informatics platform, streamlining complex workflows, unifying scientific data, and enabling faster, smarter decisions across biopharma research and development, clinical diagnostics, and manufacturing.

Trusted by global leaders and innovators worldwide, we support a wide range of best-in-class applications, from NGS and bioanalysis to bioprocessing, stability studies, histopathology, antibody discovery, and in vivo studies.

Discover how Sapio Sciences can revolutionize your lab operations at www.sapiosciences.com and follow us on LinkedIn.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

RSA at Cybertech Europe 2024

Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…

Italian Security Awards 2024: G11 Media honours the best of Italian cybersecurity

G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes

How Austria is making its AI ecosystem grow

Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries

Sparkle and Telsy test Quantum Key Distribution in practice

Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

Most read

Morning Walk Finds Its Stride as Mid-Market Brands Embrace Performance…

Morning Walk, the modern performance branding company known for building brands while driving scalable business results, announced today a surge in growth…

Glean Brings Together Industry Leaders and AI Visionaries Driving the…

Work AI leader Glean today announced its lineup of powerhouse industry speakers - from Fortune 500 CEOs to AI-first disruptors - set to take the stage…

Dassault Systèmes and Airbus Extend Strategic Partnership to Use Virtual…

#3DEXPERIENCE--Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) and Airbus have extended their long-term strategic partnership, putting the 3DEXPERIENCE…

Thesys Introduces C1 to Launch the Era of Generative UI

#AI--C1 by Thesys is the world’s first API built for Generative User Interface (GenUI), enabling developers to turn LLM outputs into live, dynamic applications…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!